Market Overview

Sunshine Biopharma Enters into Clinical Trials Agreement with the Jewish General Hospital in Montreal, Canada


Sunshine Biopharma (OTC: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials. Adva-27a is a small molecule that inhibits Topoisomerase II, an enzyme found in abundance in various types of aggressive cancer, and Adva-27a will be developed to target tumors with over-expression of this target.

Dr. Steve Slilaty, Sunshine's President and CEO, stated: "We are very excited to work with the Segal Cancer Centre of the Jewish General Hospital, one of the top cancer centres in North America.  Our Adva-27a is a much more effective inhibitor of Topoisomerase II without the adverse side effects. Data published in our issued and pending patent applications have shown that Adva-27a is significantly more effective in arresting cancer cell growth than its current market competitor."  

Dr. Slilaty also stated: "We anticipate Adva-27a to be available for compassionate-use" by the end of the trial as small-cell lung cancer patients have limited treatment options at present. We are excited by the prospects together with the long-standing history of the Jewish General to further enhance the length and quality of cancer patients in our community and throughout the world".

Posted-In: News


Related Articles (SBFM)

View Comments and Join the Discussion!

Citi Comments On Chicago Bridge & Iron Senior Management Meetings

Virgin Media Announced The Repurchase Of 325,000 Shares Of Common Stock On 16 June 2011